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Abstract: Gastroenteropancreatic neuroendocrine neoplasms
(GEP-NENs) are rare epithelial neoplasms. Grading is based on
mitotic activity or the percentage of Ki67-positive cells in a hot
spot. Routine methods have poor intraobserver and interob-
server consistency, and objective measurements are lacking. This
study aimed to evaluate digital image analysis (DIA) as an ob-
jective assessment of proliferation markers in GEP-NENs. A
consecutive cohort of patients with automated DIA measure-
ment of Ki67 (DIA Ki67) and phosphohistone H3 (DIA PHH3)
on immunohistochemical slides was analyzed using Visiopharm
image analysis software (Hoersholm, Denmark). The results
were compared with the Ki67 index from routine pathology re-
ports (pathology Ki67). The study included 159 patients (57%
males). The median pathology Ki67 was 2.0% and DIA Ki67
was 4.1%. The interclass correlation coefficient of the DIA Ki67
compared with the pathology Ki67 showed an excellent agree-
ment of 0.96 [95% confidence interval (CI): 0.94-0.96]. The ob-
served kappa value was 0.86 (95% CI: 0.81-0.91) when
comparing grades based on the same methods. PHH3 was
measured in 145 (91.2%) cases. The observed kappa value was
0.74. (95% CI: 0.65-0.83) when comparing grade based on the
DIA PHH3 and the pathology Ki67. The DIA Ki67 shows ex-
cellent agreement with the pathology Ki67. The DIA PHH3
measurements were more varied and cannot replace other
methods for grading GEP-NENs.
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Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) comprise a heterogeneous group of rare, benign,
or malignant epithelial tumors (carcinoids) originating from
the pancreas (PNENs) or gastrointestinal tract (GI-NETs).
The reported annual incidence varies between 2.39 and
5.83 per 100,000 inhabitants according to international
literature,1,2 with an estimated prevalence of 35 per 100,000
because of the long survival times. The 5-year survival rates
vary between 40% and 100% and are associated with the
primary tumor site, tumor grade, and stage of disease at the
time of diagnosis.3–5 Moreover, GEP-NENs classified as
functional tumors (which secrete hormones or peptides to
cause clinical symptoms or syndromes) show a different bio-
logical behavior from those classified as nonfunctional GEP-
NENs,6 and tumor behavior is also associated with the his-
topathologic pattern, including the features of an
adenocarcinoma.7 The diagnostic criteria of neuroendocrine
tumors are based on morphology and the positive staining of
the neuroendocrine markers synaptophysin and/or chromog-
ranin A by immunohistochemistry (IHC).8
According to the World Health Organization (WHO)
criteria, the grading of GEP-NENs is based on the evalua-
tion of mitotic activity, either by counting mitosis, the so-
called “mitotic activity index” (MAI), on hematoxylin and
eosin (HE)-stained slides or by calculating the percentage of
Ki67-positive cells in a hot spot (Table 1).9,10 The highest
grade should apply if any discordance between the MAI and
Ki67 index assessment occurs.10 The Ki67 index predicts
prognosis better than MAI.11
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One of the challenges related to the current routine
grading procedure is the time-consuming counting of >500
cells by a pathologist, which may lead to an eyeball esti-
mation as a short-cut in a busy routine practice. Moreover,
the identification of “hot spots” in a section may be
difficult,12 which may partly explain the reported poor in-
traobserver and interobserver reliability.13 Consequently,
objective measurements, including digital image analysis
(DIA), are warranted for accurate grade reporting.
The heterogeneous biological behavior of GEP-NENs
has encouraged a search for better prognostic markers. Phos-
phohistone H3 (PHH3) has been identified as a promising
marker for the prediction of disease-free survival and disease-
specific survival in PNENs.14,15 In contrast to Ki67, which is
present in cell nuclei in the G1, S, G2, and M phases of the cell
cycle, PHH3 stains mitotic cells (M phase). Thus, with PHH3,
mitotic activity can be specifically determined;16 therefore,
PHH3 has been suggested as an alternative to the Ki67 index in
PNENs.17 Furthermore, counting MAI is challenging because
apoptotic figures can be misidentified as mitotic figures.17,18
PHH3 does not stain apoptotic cells and can therefore be a
better biomarker for mitosis than MAI. Several studies have
shown good concordance between the number of mitoses and
PHH3.19,20 Accordingly, PHH3 is regarded as promising for
the assessment of grading in GEP-NENs in general.
In this study, we evaluated and compared the DIA
Ki67 with the routine procedure for the Ki67 index as-
sessment (pathology Ki67). In addition, we applied DIA
for PHH3 assessment (DIA PHH3) to explore possible
associations between PHH3 and the Ki67 index to eval-
uate the potential advantages or challenges of PHH3 as a
proliferation marker in routine practice.
MATERIALS AND METHODS
Ethical Approval
All procedures performed in studies involving human
participants were per the ethical standards of the institutional
and/or National Research Committee and the 1964 Helsinki
Declaration and its later amendments or comparable ethical
standards. This project was approved by the Regional Ethics
Committee of the Western Health Authority (REK 2016/
1622). Patients still alive have signed a written consent form to
participate.
Materials
We identified all consecutive patients diagnosed with
GEP-NENs and treated at Stavanger University Hospital
from 2003 to 2013. The hospital serves as the only hospital
for a well-defined Norwegian population of ∼380,000
people.2 Of 204 consecutive patients during that period, 35
declined to participate. In addition, 1 patient was excluded
because of the possibility of primary pulmonary neuro-
endocrine carcinoma, and 9 patients were excluded be-
cause of a lack of tissue for analysis. Thus, 159 (77.9%)
patients were included.
Archived formalin-fixed paraffin-embedded tissue from
the hospital’s diagnostic biobank was obtained. The current
WHO criteria for neuroendocrine tumors10 were used, and
pathologic tumor-node-metastasis (TNM) staging was per-
formed according to the American Joint Committee on Cancer
(AJCC) 8th edition.21 For Ki67, 500 to 2000 tumor cells were
assessed in hot spots by microscopic evaluation.21 The Ki67
index was retrieved from the original routine pathology reports,
and cases without available information were re-evaluated to
complete pertinent information on all patients, as reported in
our previous study.2
All tumors were confirmed as NENs by positive IHC
staining for synaptophysin and/or chromogranin A. Neuro-
endocrine carcinoma was included as grade 3 (high grade).
Mixed neuroendocrine–non‐neuroendocrine neoplasms were
excluded. The sample included 63 (39.6%) biopsies and 96
(60.4%) surgical specimens. MAI was not evaluated because
of the high number of biopsies with an area <10mm2.
Methods
IHC
Ki67. The MIB-1 clone (Dako, Glostrup, Denmark)
was used for routine staining at the Department of Pathol-
ogy. The method has had minor changes in processing from
2003 to 2013, but the MIB-1 clone has been the same. The
MIB-1 clone is validated for GEP-NEN grading.22,23
PHH3. Antigen retrieval and antibody dilution were
optimized before study onset. Paraffin sections adjacent to
the HE sections were cut into 2-µm-thick sections and
mounted on Superfrost Plus slides. The slides were in-
cubated at 60°C for 1 hour and stained using a Dako
Omnis immunostainer. PHH3 (nr. 06-570; Merck Group,
Darmstadt, Germany) was used at a dilution of 1:5000.
The Dako EnVision Flex+ (Dako GV80011-2) detection
system was used in line with the recommendations of the
manufacturer.
DIA
IHC staining of Ki67 was already performed, and
the available archived sections were retrieved from the
hospital’s archive. HE sections, Ki67, and PHH3 were
scanned at ×40 magnification using a Leica SCN400 slide
TABLE 1. WHO Grading of Neuroendocrine Tumors
(WHO 2019)
Grade Mitotic Activity, Per 2 mm2* Ki67%*
NET Grade 1 Low 1 < 3
NET Grade 2 Intermediate 2-20 3-20
NET Grade 3 High > 20 > 20
LCNEC High† > 20 > 20
SCNEC High† > 20 > 20
MiNEN Variable Variable Variable
*Mitotic rates are expressed as the number of mitoses/2 mm2 as determined by
counting in 50 fields of 0.2 mm2 (ie, in a total area of 10 mm2); the Ki67 pro-
liferation index value is determined by counting at least 500 cells in the regions of
highest labeling (hot spots), which are identified at scanning magnification.
†Poorly differentiated NECs are not formally graded but are considered high‐
grade by definition.
LCNEC indicates large‐cell neuroendocrine carcinoma; MiNEN, mixed
neuroendocrine–non‐neuroendocrine neoplasm; NEC, neuroendocrine carcinoma;
NET, neuroendocrine tumor; SCNEC, small‐cell neuroendocrine carcinoma;
WHO, World Health Organization.
Lea et al Appl Immunohistochem Mol Morphol  Volume 29, Number 7, August 2021
500 | www.appliedimmunohist.com Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc.
scanner (Leica Biosystems, Wetzlar, Germany) and up-
loaded to the image analysis software (Visiopharm,
Hoersholm, Denmark). The person responsible for the
DIA evaluation (D.L.) was blinded to the previously re-
ported routine Ki67 index results and other parameters
when DIA was performed. Patients were excluded from
the DIA if there was insufficient tumor material for
analysis (< 500 tumor cells). If a biopsy material and not a
surgical specimen was used for the original routine Ki67
evaluation, DIA was also performed on the biopsy sam-
ple, given that sufficient materials were available.
For Ki67, the percentage of positive tumor cells was
measured in the hot spot of the tumor in an area that
includes 500 to 2000 tumor cells with the Visiopharm
program (Fig. 1). The software program identified positive
nuclei (label 1) and negative nuclei (label 2) within a
manually selected area named the region of interest (ROI).
Stroma and stromal cells were excluded from the ROI by
the software program so that only the tumor cells were
evaluated, similar to our DIA Ki67 method described for
breast cancer.12 The percentage of tumor cells was
calculated. If the hot spot was ill-defined on a slide, the
measurement was repeated in different areas, and the area
with the highest positivity was counted. The program
measured the areas of positive and negative nuclei, and
based on the size of the nuclei in each tumor, an estimate
of tumor cells was calculated. A percentage was calculated
from ∼2000 tumor cells. If there were <2000 cells but
> 500 cells, a percentage was given based on the available
cells in the section. This value was compared with the
pathology Ki67 (regarded as the gold standard).
The number of PHH3-positive cells was calculated in 4
different ROIs of 2mm2 (ROI: 1 to 4) (Fig. 2). The different
ROIs were chosen subjectively from the visual identification of
areas with the highest number of PHH3-positive cells. The
number of PHH3-positive cells within each ROI was
calculated. If there was insufficient material for 4 ROIs,
fewer ROIs were chosen for measurement. For PHH3,
Visiopharm was programmed to detect IHC-stained mitotic
cells as described by others.24 Cells in all 4 substages of
mitosis, prophase, metaphase, anaphase, and telophase, were
regarded as positive.25 Objects smaller than mitotic figures
were removed by a size filter. The remaining objects were
dilated to fuse the chromatin structures of cells in anaphase or
telophase into 1 object. All remaining objects were counted,
and the number of objects per 2mm2 was calculated. The
counted objects were encircled in the original image, allowing
a visual inspection of the counted mitotic cells. Apart from the
manual selection of the 4 different ROIs, the DIA procedure
and all calculations were fully automated.
Statistics
IBM SPSS Statistics for Windows, Version 26.0 (IBM
Corporation, Armonk, NY) was used for statistical calcu-
lations. The quadratically weighted kappa was used to mea-
sure the agreement between ordinal variables.26 The interclass
correlation coefficient was used to measure the agreement
between continuous variables (single rater, absolute agree-
ment). All agreement estimates are presented with 95% con-
fidence intervals (CIs). Values <0.50, between 0.50 and 0.75,
between 0.75 and 0.90, and >0.90 indicated poor, moderate,
good, and excellent reliability, respectively.27 To plot the dif-
ference in pathology Ki67 and DIA Ki67 measurement
against average value, we used a Bland-Altman plot.28
RESULTS
The clinicopathologic characteristics of the patients are
shown in Table 2. The distribution of grading based on the
DIA Ki67, DIA PHH3, and pathology Ki67 are shown in
Figure 3. This figure shows that different methods influence
grading, with more grade 2 tumors and fewer grade 1 tumors
with the methods based on DIA than with the pathology
Ki67. The median pathology Ki67 was 2.0% (range: 1.0% to
100%). The median DIA Ki67 value was 4.1% (range: 0.0%
FIGURE 1. A, Hematoxylin and eosin staining of a grade 2
neuroendocrine tumor. B and C Immunohistochemical staining
of Ki67 with digital image analyses performed on the same
tumor. Black arrows point to some of the positive cells.
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to 99.9%). The interclass correlation coefficient of the DIA
Ki67 and pathology Ki67 showed an excellent agreement of
0.96 (95% CI: 0.94-0.98). Figure 4A shows a scatter plot of
the distribution of the DIA Ki67 and pathology Ki67. The
observed kappa between grading based on the DIA Ki67
and the pathology Ki67 was 0.86 (95% CI: 0.81-0.91).
FIGURE 2. A, Hematoxylin and eosin staining of a grade 2 neuroendocrine tumor. B, Digital image measurement of im-
munohistochemically stained phosphohistone H3 in 4 different regions of interest. C, Close-up image of hematoxylin and eosin
staining with marking of mitosis. D and E, Close-up image of the measurement of phosphohistone H3 in the regions of interest with
the highest mitotic activity.
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A Bland-Altman plot was created to visualize the difference
in agreement against average value of pathology Ki67 and
DIA Ki67 (Fig. 5).
The agreement between grading based on the DIA
Ki67 and the pathology Ki67 is shown in Table 3. None of
the grade 3 tumors was graded as grade 1 and vice versa.
Cases with less correlation between the methods
comprised mostly grade 1 and grade 2 tumors, and the
percentage was mostly measured higher (ie, > 3%) by DIA
than with the pathology Ki67. Among 26 cases with a
discrepancy between grades 1 and 2, Ki67 values of 2% to
TABLE 2. Demographics and Clinical Characteristics of the
Patients
Characteristics Value




Tumor size, median* (range), cm 1.7 (0.1-13.8)










Metastasis liver/unknown primary 7 (4.4)









N classification*, n (%)
N0 69 (44.5)
N1 86 (55.5)
M classification*, n (%)
M0 95 (61.3)
M1 60 (38.7)





*Numbers may not add up because of missing data: n= 18 for tumor size,
n= 23 for T-stage, n= 4 for N-stage and M-stage and n= 2 for AJCC stage.
AJCC indicates American Joint Committee on Cancer; WHO, World Health
Organization.
FIGURE 3. Comparison of World Health Organization (WHO)
grading based on different methods for proliferation meas-
urement. PHH3 indicates phosphohistone H3.
FIGURE 4. A, Scatter plot showing the correlation between the
Ki67 index from the pathology report and Ki67 based on
digital image analysis. B, Scatter plot showing the correlation
between the Ki67 index from the pathology report and digital
measurement of the number of phosphohistone H3 (PHH3)-
positive cells per 2mm2.
FIGURE 5. A Bland-Altman plot showing the difference Ki67
index against mean value from the pathology report and Ki67
based on digital image analysis.
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4% were found in 24 (92.3%) of the cases by either DIA
Ki67 or pathology Ki67.
PHH3 was measured in 145 (145/159=91.2%) of the
patients. Fourteen patients were excluded because of a lack
of available tumor material for analysis. A median of 3
mitoses (range: 0 to 678 cells/mm2) was observed. Figure 4B
shows a scatter plot of the distribution of DIA PHH3 and
the pathology Ki67. The observed kappa between grading
based on the DIA PHH3 and pathology Ki67 was 0.742.
(95% CI: 0.65-0.83). The agreement between grading based
on DIA PHH3 and the pathology Ki67 is shown in Table 4.
For the DIA of PHH3, there were no grade 3 tumors that
were graded as grade 1. Moreover, 35 NENs were upgraded
from grade 1 to grade 2 based on the DIA PHH3
measurement compared with pathology Ki67. In 20 (20/
35=57.1%) of these tumors, the PHH3 value was 2 or 3.
DISCUSSION
The current study explored several comparative mea-
sures for grading by the use of DIA and alternative markers
for proliferation. Grading based on the DIA Ki67 showed
good reliability compared with grading based on the path-
ology Ki67. The use of DIA PHH3 for grading did not show
similar results, with a higher number of NENs migrating
between grades, especially grade 2, as a consequence.
Whether this represents true grade migration or just artefacts
from variation in scores remains unproven.
This study confirms an excellent agreement between
the DIA Ki67 and the pathology Ki67, a finding that is
supported by other studies.13,29 DIA can improve the re-
liability and reproducibility of grading in routine
practice.30 Thus, likely the pathology departments with
this method or similar DIA available, can use DIA Ki67
as a part of their routine diagnostics. Digital pathology
has during recent years, been introduced at more pathol-
ogy departments, and the numbers are increasing.31,32
Manual counting is often difficult because of the high
cellularity commonly encountered in these tumors.30 One
of the benefits of our DIA method of Ki67 is the auto-
matic separation of stroma and stromal cells from tumor
cells. This does not apply to all DIAs, which may partly
explain the previously reported poor concordance between
the DIA and manual analysis of Ki67 found by others.33
This study included a consecutive series from a pop-
ulation-representative cohort of GEP-NEN patients in a
well-defined region of Norway. Compared with other studies
of GEP-NENs, the number of included patients with grades
2 and 3 was high, and the distribution of different grades was
more even.13,17,30,33–35 A limitation of our study is that al-
most 40% of the tumor samples were from biopsies. How-
ever, this is in line with current routine practice at many
centers since surgical specimens are not achievable for all
patients, especially patients with advanced disease.
Grading based on the DIA PHH3 agreed less well with
the WHO grade based on the pathology Ki67. This is in line
with the results of others.15,33,36 Accordingly, we believe the
DIA and use of PHH3 are not supported for routine use or as
an alternative in GEP-NEN grading. Some of the cases with
low Ki67 had high PHH3. Others have reported a specific
value for PHH3 in PNENs,14 but we could not confirm or
refute this based on the limited number of PNENs.
For both DIA Ki67 and DIA PHH3, the proportion
of grade 2 tumors was higher than the routinely reported
grading. This illustrates the difficulty in separating grade 1
and grade 2 tumors.33,37 A factor that might explain this
finding is that the DIA method makes it easier to identify a
hot spot than manual evaluation in a busy routine practice.
With DIA, measurements can be repeated or several areas
can be measured if the hot spot is difficult to identify. The
size of the hot spot (500 to 2000 cells) might also influence
the grading. A study of G1 and G2 PNENs found that DIA
overestimated the Ki67 index compared with manual eval-
uation. The difference was reduced by increasing the size of
the hot spot.38 Kroneman et al37 found that eyeball esti-
mations of Ki67 tended to downgrade more NETs to grade
1 than evaluations by DIA. These studies support our find-
ings. In many cases with a discrepancy, the value of Ki67 or
PHH3 was near the cut-off level for the grading criteria.
Discussions are ongoing regarding which method should be
regarded as the gold standard.13,34,35 For breast cancers,
there is a debate about whether the manual analysis of Ki67
should be the gold standard since several studies have shown
superior prognostic information from DIA.39,40
In conclusion, standardized DIA Ki67 scoring gave
similar results as subjective scoring but may be a time-saving
supplementary tool in surgical pathology29 that can improve
the poor intraobserver and interobserver reliability with
manual evaluation methods.41 DIA PHH3 do not agree so
well with routine grading and is not recommended as an
alternative to MAI or Ki67 in routine practice.
TABLE 3. Agreement Between Grading of Tumors Based on
Digital Image Analysis of Ki67 and Grading From Routine
Pathology Reports
Grade (DIA Ki67) n, (%)
1 2 3 Total, n (%)
Grade (routine)
1 63 (39.6) 22 (13.8) 0 85 (53.5)
2 4 (2.5) 33 (20.8) 1 (0.6) 38 (23.9)
3 0 1 (0.6) 35 (22.0) 36 (22.6)
Total 67 (42.1) 56 (35.2) 36 (22.6) 159
DIA indicates digital image analysis.
TABLE 4. Agreement Between Grading of Tumors Based on
Digital Image Analysis of Phosphohistone H3 and Grading from
Routine Pathology Reports
Grade (DIA PHH3) n, (%)
1 2 3 Total n, (%)
Grade (routine)
1 43 (29.7) 35 (24.1) 0 78 (53.8)
2 4 (2.8) 28 (19.3) 4 (2.8) 36 (24.8)
3 0 3 (2.1) 28 (19.3) 31 (21.4)
Total 47 (32.4) 66 (45.5) 32 (22.1) 145
DIA indicates digital image analysis; PHH3, phosphohistone H3.
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